✨ Medicines Distribution Consents




2784
NEW ZEALAND GAZETTE
No. 91

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Spirapril 6 mg Tablet Sandoz Pharma Limited, Basle, Switzerland Sandopril
Diclofenac sodium 100 mg Tablet (sustained release) Laboratoria Wolfs B V B A, Antwerp, Belgium Difen SR
Selegiline hydrochloride 5 mg Tablet Apotex Inc., Weston, Ontario, Canada Apo-Selegiline
Nifedipine 10 mg Tablet Hexal-Pharma GmbH, Holzkirchen, Germany Fedrem
Flecainide acetate 50 mg Capsule Pacific Pharmaceuticals Limited, Mt Wellington, Auckland Tabco 50
Note: Not to be marketed as substitutable for any other flecainide acetate product as if the two (2) products were bioequivalent.
Flecainide acetate 100 mg Tablet Pacific Pharmaceuticals Limited, Mt Wellington, Auckland Tabco 100
Note: Not to be marketed as substitutable for any other flecainide acetate product as if the two (2) products were bioequivalent.
Rocuronium bromide 50 mg in 5 ml, 100 mg in 10 ml Injection N V Organon, Oss, The Netherlands and Organon Laboratories Limited, Newhouse, Motherwell, Lanarkshire, Scotland Esmeron

Dated this 2nd day of September 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g06649

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Pentastarch 10% Solution for infusion Nederlands Productielaboratorium Voor Bloedtransfusieapparatuur en Infusieevloeistoffen BV (NPBI BV), Emmer-Compascuum, The Netherlands Pentaspan

Dated this 31st day of August 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g06651

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
300 mcg Anti D (Rhβ‚€) Immunoglobulin (>820IU) Solution for IM injection Ortho Diagnostics Inc., Raritan, New Jersey, United States of America RhoGAM

Conditions:

  1. The above provisional consent is valid for six (6) months from the date of publication of this notice.

  2. The health care professional who prescribes or administers RhoGAM must report its use to Auckland Healthcare Limited on a standardised form. The standardised form must contain the name and address of the health care professional and patient, and the reason, place and date of administration.

  3. On a monthly basis, Auckland Healthcare Limited are required to forward the user information forms to the Ministry of Health along with information detailing the amounts of RhoGAM distributed and the sites to which it was distributed.

Dated this 1st day of September 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g06652



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1994, No 91


NZLII PDF NZ Gazette 1994, No 91





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
2 September 1994
Medicines, Distribution, Consent, Medicines Act 1981
  • C. Lovelace, Director-General of Health

πŸ₯ Provisional Consent to the Distribution of Pentastarch 10%

πŸ₯ Health & Social Welfare
31 August 1994
Medicines, Distribution, Consent, Pentastarch, Medicines Act 1981
  • C. Lovelace, Director-General of Health

πŸ₯ Provisional Consent to the Distribution of RhoGAM

πŸ₯ Health & Social Welfare
1 September 1994
Medicines, Distribution, Consent, RhoGAM, Medicines Act 1981
  • C. Lovelace, Director-General of Health